New method to deliver a treatment for Alzheimer's disease
Official title: Develop a novel strategy to deliver N-acetylcysteine for AD treatment
Funded at Acepre, LLC · NIH-11012575 · Data updated 2026-11-12
This study is working on a new way to deliver a helpful supplement called N-acetylcysteine (NAC) directly to the brain to see if it can improve brain health for people with Alzheimer's disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Acepre, LLC NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | September 15, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $499,441 |
| NIH project number | 1R41AG087769-01A1 |
| Project ID | NIH-11012575 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those in the early to moderate stages of the condition.
✕Less likely to help
Patients with advanced Alzheimer's disease or those who do not have a diagnosis of Alzheimer's may not benefit from this research.
What this research studies
This research focuses on developing a novel delivery system for N-acetylcysteine (NAC) to treat Alzheimer's disease (AD). NAC has shown promise due to its antioxidant and anti-inflammatory properties, but it struggles to cross the blood-brain barrier effectively. The study aims to create a targeted delivery system that allows NAC to reach the brain and potentially improve the health of brain cells affected by AD. By addressing the underlying toxicities associated with AD, this approach hopes to provide a more effective treatment option for patients.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for Alzheimer's disease, potentially improving patient outcomes and quality of life.
How similar studies have gone: While the approach of using NAC for Alzheimer's treatment has been explored, the specific targeted delivery system being developed is novel and has not been extensively tested in this context.
Where this research is happening
-
Acepre, LLC
Columbia, United States Active
Researchers
- Principal investigator: Xu, Peisheng — Acepre, LLC
- Study coordinator: Xu, Peisheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.